Drug Profile

Temsirolimus polymeric micelle - Samyang Biopharmaceuticals

Latest Information Update: 10 Apr 2025

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Samyang Biopharmaceuticals Corporation
Class Antineoplastics; Macrolides
Mechanism of Action MTOR protein inhibitors

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity No
Available For Licensing Yes

Highest Development Phases

Discontinued Cancer

Most Recent Events

10 Apr 2025 Discontinued - Preclinical for Cancer in South Korea (unspecified route), before April 2025
28 Feb 2023 No recent reports of development identified for preclinical development in Cancer in South Korea
17 Jan 2019 Temsirolimus polymeric micelle is available for licensing as of 17 Jan 2019. http://www.samyangbiopharm.com/

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com